Role of cold shock Y-box protein-1 in inflammation, atherosclerosis and organ transplant rejection

European Journal of Cell Biology

Volumn 91, Issue 6-7, 2012, Pages 567-575

  Raffetseder, Ute ^a   Liehn, Elisa A ^a   Weber, Christian ^a,b,c   Mertens, Peter R ^d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Munich Heart Alliance   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Graft rejection; Inflammation; RANTES CCL5; Transcription factor; YB 1

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P53; RANTES; THIOREDOXIN 1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR YY1; TUMOR NECROSIS FACTOR ALPHA; Y BOX BINDING PROTEIN 1;

ALLERGIC ASTHMA; ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; GENE CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY GRAFT REJECTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; MONOCYTE; NEOINTIMA; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; SHORT SURVEY;

ANIMALS; ATHEROSCLEROSIS; CHEMOKINE CCL5; CHEMOKINES; GRAFT REJECTION; HUMANS; INFLAMMATION; MICE; Y-BOX-BINDING PROTEIN 1;

EID: 84860248607     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.07.001     Document Type: Short Survey

References (104)

1. Ammit A.J., Lazaar A.L., Irani C., O'Neill G.M., Gordon N.D., Amrani Y., Penn R.B., Panettieri R.A. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am. J. Respir. Cell Mol. Biol. 2002, 26:465-474.
2. Baltus T., Weber K.S., Johnson Z., Proudfoot A.E., Weber C. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 2003, 102:1985-1988.
3. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dorken B., Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 1997, 3:447-450.
4. Basaki Y., Hosoi F., Oda Y., Fotovati A., Maruyama Y., Oie S., Ono M., Izumi H., Kohno K., Sakai K., Shimoyama T., Nishio K., Kuwano M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007, 26:2736-2746.
5. Bayarsaihan D., Enkhmandakh B., Lukens L.N. Y-box proteins interact with the S1 nuclease-sensitive site in the chicken alpha 2(I) collagen gene promoter. Biochem. J. 1996, 319(Pt 1):203-207.
6. Belperio J.A., Burdick M.D., Keane M.P., Xue Y.Y., Lynch J.P., Daugherty B.L., Kunkel S.L., Strieter R.M. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J. Immunol. 2000, 165:461-472.
7. Berquin I.M., Pang B., Dziubinski M.L., Scott L.M., Chen Y.Q., Nolan G.P., Ethier S.P. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005, 24:3177-3186.
8. Boehlk S., Fessele S., Mojaat A., Miyamoto N.G., Werner T., Nelson E.L., Schlondorff D., Nelson P.J. ATF and Jun transcription factors, acting through an Ets/CRE promoter module, mediate lipopolysaccharide inducibility of the chemokine RANTES in monocytic Mono Mac 6 cells. Eur. J. Immunol. 2000, 30:1102-1112.
9. Botker H.E., Kharbanda R., Schmidt M.R., Bottcher M., Kaltoft A.K., Terkelsen C.J., Munk K., Andersen N.H., Hansen T.M., Trautner S., Lassen J.F., Christiansen E.H., Krusell L.R., Kristensen S.D., Thuesen L., Nielsen S.S., Rehling M., Sorensen H.T., Redington A.N., Nielsen T.T. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010, 375:727-734.
10. Bousquet J., Chanez P., Lacoste J.Y., Barneon G., Ghavanian N., Enander I., Venge P., Ahlstedt S., Simony-Lafontaine J., Godard P., et al. Eosinophilic inflammation in asthma. N. Engl. J. Med. 1990, 323:1033-1039.
11. Braunersreuther V., Steffens S., Arnaud C., Pelli G., Burger F., Proudfoot A., Mach F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1090-1096.
12. Braunersreuther V., Zernecke A., Arnaud C., Liehn E.A., Steffens S., Shagdarsuren E., Bidzhekov K., Burger F., Pelli G., Luckow B., Mach F., Weber C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:373-379.
13. Braunersreuther V., Pellieux C., Pelli G., Burger F., Steffens S., Montessuit C., Weber C., Proudfoot A., Mach F., Arnaud C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J. Mol. Cell. Cardiol. 2010, 48:789-798.
14. Canavese M., Altruda F., Silengo L. Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction. PLoS One 2010, 5:e8725.
15. Capowski E.E., Esnault S., Bhattacharya S., Malter J.S. Y box-binding factor promotes eosinophil survival by stabilizing granulocyte-macrophage colony-stimulating factor mRNA. J. Immunol. 2001, 167:5970-5976.
16. Cavusoglu E., Eng C., Chopra V., Clark L.T., Pinsky D.J., Marmur J.D. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler. Thromb. Vasc. Biol. 2007, 27:929-935.
17. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
18. Chen C.Y., Gherzi R., Andersen J.S., Gaietta G., Jurchott K., Royer H.D., Mann M., Karin M. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev. 2000, 14:1236-1248.
19. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
20. Coles L.S., Diamond P., Lambrusco L., Hunter J., Burrows J., Vadas M.A., Goodall G.J. A novel mechanism of repression of the vascular endothelial growth factor promoter, by single strand DNA binding cold shock domain (Y-box) proteins in normoxic fibroblasts. Nucleic Acids Res. 2002, 30:4845-4854.
21. Coles L.S., Diamond P., Occhiodoro F., Vadas M.A., Shannon M.F. Cold shock domain proteins repress transcription from the GM-CSF promoter. Nucleic Acids Res. 1996, 24:2311-2317.
22. Coles L.S., Lambrusco L., Burrows J., Hunter J., Diamond P., Bert A.G., Vadas M.A., Goodall G.J. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett. 2005, 579:5372-5378.
23. Diamond P., Shannon M.F., Vadas M.A., Coles L.S. Cold shock domain factors activate the granulocyte-macrophage colony-stimulating factor promoter in stimulated Jurkat T cells. J. Biol. Chem. 2001, 276:7943-7951.
24. Didier D.K., Schiffenbauer J., Woulfe S.L., Zacheis M., Schwartz B.D. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:7322-7326.
25. Dobaczewski M., Xia Y., Bujak M., Gonzalez-Quesada C., Frangogiannis N.G. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am. J. Pathol. 2010, 176:2177-2187.
26. el-Sawy T., Fahmy N.M., Fairchild R.L. Chemokines: directing leukocyte infiltration into allografts. Curr. Opin. Immunol. 2002, 14:562-568.
27. En-Nia A., Yilmaz E., Klinge U., Lovett D.H., Stefanidis I., Mertens P.R. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J. Biol. Chem. 2005, 280:7702-7711.
28. Esnault S., Malter J.S. Hyaluronic acid or TNF-alpha plus fibronectin triggers granulocyte macrophage-colony-stimulating factor mRNA stabilization in eosinophils yet engages differential intracellular pathways and mRNA binding proteins. J. Immunol. 2003, 171:6780-6787.
29. Fessele S., Boehlk S., Mojaat A., Miyamoto N.G., Werner T., Nelson E.L., Schlondorff D., Nelson P.J. Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells. FASEB J. 2001, 15:577-579.
30. Fraser D.J., Phillips A.O., Zhang X., van Roeyen C.R., Muehlenberg P., En-Nia A., Mertens P.R. Y-box protein-1 controls transforming growth factor-beta1 translation in proximal tubular cells. Kidney Int. 2008, 73:724-732.
31. Frye B.C., Halfter S., Djudjaj S., Muehlenberg P., Weber S., Raffetseder U., En-Nia A., Knott H., Baron J.M., Dooley S., Bernhagen J., Mertens P.R. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009, 10:783-789.
32. Gaikwad J.S., Fotedar A. Cloning of a T-cell receptor beta-chain enhancer binding protein. Gene 1997, 204:79-83.
33. Genin P., Algarte M., Roof P., Lin R., Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors. J. Immunol. 2000, 164:5352-5361.
34. Grone H.J., Weber C., Weber K.S., Grone E.F., Rabelink T., Klier C.M., Wells T.N., Proudfood A.E., Schlondorff D., Nelson P.J. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 1999, 13:1371-1383.
35. Hall B.M. Cells mediating allograft rejection. Transplantation 1991, 51:1141-1151.
36. Hanssen L., Frye B.C., Ostendorf T., Alidousty C., Djudjaj S., Boor P., Rauen T., Floege J., Mertens P.R., Raffetseder U. Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney. J. Immunol. 2011, 187:298-308.
37. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., Jones P.L., Maitland M.L., Michelakis E.D., Morrell N.W., Newman J.H., Rabinovitch M., Schermuly R., Stenmark K.R., Voelkel N.F., Yuan J.X., Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 2009, 54:S10-S19.
38. Higashi K., Inagaki Y., Fujimori K., Nakao A., Kaneko H., Nakatsuka I. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J. Biol. Chem. 2003, 278:43470-43479.
39. Higashi K., Inagaki Y., Suzuki N., Mitsui S., Mauviel A., Kaneko H., Nakatsuka I. Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) collagen gene expression by interferon-gamma. J. Biol. Chem. 2003, 278:5156-5162.
40. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., Littman D.R., Weber C., Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med. 2003, 9:61-67.
41. Jenkins R.H., Bennagi R., Martin J., Phillips A.O., Redman J.E., Fraser D.J. A conserved stem loop motif in the 5'untranslated region regulates transforming growth factor-beta(1) translation. PLoS One 2010, 5:e12283.
42. Kamalov G., Varma B.R., Lu L., Sun Y., Weber K.T., Guntaka R.V. Expression of the multifunctional Y-box protein, YB-1, in myofibroblasts of the infarcted rat heart. Biochem. Biophys. Res. Commun. 2005, 334:239-244.
43. Kloks C.P., Spronk C.A., Lasonder E., Hoffmann A., Vuister G.W., Grzesiek S., Hilbers C.W. The solution structure and DNA-binding properties of the cold-shock domain of the human Y-box protein YB-1. J. Mol. Biol. 2002, 316:317-326.
44. Kloks C.P., Tessari M., Vuister G.W., Hilbers C.W. Cold shock domain of the human Y-box protein YB-1. Backbone dynamics and equilibrium between the native state and a partially unfolded state. Biochemistry 2004, 43:10237-10246.
45. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., Kramp B.K., Piccinini A.M., Paludan S.R., Kowalska M.A., Kungl A.J., Hackeng T.M., Mayo K.H., Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009, 15:97-103.
46. Kohno K., Izumi H., Uchiumi T., Ashizuka M., Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003, 25:691-698.
47. Kramp B.K., Sarabi A., Koenen R.R., Weber C. Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp. Cell Res. 2011, 317:655-663.
48. Krensky A.M., Ahn Y.T. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat. Clin. Pract. Nephrol. 2007, 3:164-170.
49. Krohn R., Raffetseder U., Bot I., Zernecke A., Shagdarsuren E., Liehn E.A., van Santbrink P.J., Nelson P.J., Biessen E.A., Mertens P.R., Weber C. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 2007, 116:1812-1820.
50. Lasham A., Lindridge E., Rudert F., Onrust R., Watson J. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000, 252:1-13.
51. Lee A.H., Hong J.H., Seo Y.S. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Biochem. J. 2000, 350(Pt 1):131-138.
52. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
53. Li W.W., Hsiung Y., Wong V., Galvin K., Zhou Y., Shi Y., Lee A.S. Suppression of grp78 core promoter element-mediated stress induction by the dbpA and dbpB (YB-1) cold shock domain proteins. Mol. Cell. Biol. 1997, 17:61-68.
54. Liehn E.A., Merx M.W., Postea O., Becher S., Djalali-Talab Y., Shagdarsuren E., Kelm M., Zernecke A., Weber C. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J. Cell. Mol. Med. 2008, 12:496-506.
55. Liverman C.S., Kaftan H.A., Cui L., Hersperger S.G., Taboada E., Klein R.M., Berman N.E. Altered expression of pro-inflammatory and developmental genes in the fetal brain in a mouse model of maternal infection. Neurosci. Lett. 2006, 399:220-225.
56. Lu Z.H., Books J.T., Ley T.J. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol. Cell. Biol. 2005, 25:4625-4637.
57. MacDonald G.H., Itoh-Lindstrom Y., Ting J.P. The transcriptional regulatory protein, YB-1, promotes single-stranded regions in the DRA promoter. J. Biol. Chem. 1995, 270:3527-3533.
58. Makino Y., Cook D.N., Smithies O., Hwang O.Y., Neilson E.G., Turka L.A., Sato H., Wells A.D., Danoff T.M. Impaired T cell function in RANTES-deficient mice. Clin. Immunol. 2002, 102:302-309.
59. Matsumoto K., Wolffe A.P. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol. 1998, 8:318-323.
60. Mertens P.R., Alfonso-Jaume M.A., Steinmann K., Lovett D.H. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J. Biol. Chem. 1998, 273:32957-32965.
61. Mertens P.R., Alfonso-Jaume M.A., Steinmann K., Lovett D.H. YB-1 regulation of the human and rat gelatinase A genes via similar enhancer elements. J. Am. Soc. Nephrol. 1999, 10:2480-2487.
62. Mertens P.R., Harendza S., Pollock A.S., Lovett D.H. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J. Biol. Chem. 1997, 272:22905-22912.
63. Miyamoto N.G., Medberry P.S., Hesselgesser J., Boehlk S., Nelson P.J., Krensky A.M., Perez H.D. Interleukin-1beta induction of the chemokine RANTES promoter in the human astrocytoma line CH235 requires both constitutive and inducible transcription factors. J. Neuroimmunol. 2000, 105:78-90.
64. Mulligan M.S., McDuffie J.E., Shanley T.P., Guo R.F., Vidya Sarma J., Warner R.L., Ward P.A. Role of RANTES in experimental cardiac allograft rejection. Exp. Mol. Pathol. 2000, 69:167-174.
65. Nelson P.J., Kim H.T., Manning W.C., Goralski T.J., Krensky A.M. Genomic organization and transcriptional regulation of the RANTES chemokine gene. J. Immunol. 1993, 151:2601-2612.
66. Nelson P.J., Krensky A.M. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001, 14:377-386.
67. Nickel W. The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur. J. Biochem. 2003, 270:2109-2119.
68. Nikolcheva T., Pyronnet S., Chou S.Y., Sonenberg N., Song A., Clayberger C., Krensky A.M. A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes. J. Clin. Invest. 2002, 110:119-126.
69. Norman J.T., Lindahl G.E., Shakib K., En-Nia A., Yilmaz E., Mertens P.R. The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. J. Biol. Chem. 2001, 276:29880-29890.
70. Ohmori M., Shimura H., Shimura Y., Kohn L.D. A Y-box protein is a suppressor factor that decreases thyrotropin receptor gene expression. Mol. Endocrinol. 1996, 10:76-89.
71. Okamoto T., Izumi H., Imamura T., Takano H., Ise T., Uchiumi T., Kuwano M., Kohno K. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000, 19:6194-6202.
72. Pattison J., Nelson P.J., Huie P., von Leuttichau I., Farshid G., Sibley R.K., Krensky A.M. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 1994, 343:209-211.
73. Raffetseder U., Frye B., Rauen T., Jurchott K., Royer H.D., Jansen P.L., Mertens P.R. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J. Biol. Chem. 2003, 278:18241-18248.
74. Raffetseder U., Rauen T., Boor P., Ostendorf T., Hanssen L., Floege J., En-Nia A., Djudjaj S., Frye B.C., Mertens P.R. Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. Nephron Exp. Nephrol. 2011, 118:e100-e108.
75. Raffetseder U., Rauen T., Djudjaj S., Kretzler M., En-Nia A., Tacke F., Zimmermann H.W., Nelson P.J., Frye B.C., Floege J., Stefanidis I., Weber C., Mertens P.R. Differential regulation of chemokine CCL5 expression in monocytes/macrophages and renal cells by Y-box protein-1. Kidney Int. 2009, 75:185-196.
76. Raj G.V., Safak M., MacDonald G.H., Khalili K. Transcriptional regulation of human polyomavirus JC: evidence for a functional interaction between RelA (p65) and the Y-box-binding protein, YB-1. J. Virol. 1996, 70:5944-5953.
77. Rauen T., Raffetseder U., Frye B.C., Djudjaj S., Muehlenberg P.J., Eitner F., Lendahl U., Bernhagen J., Dooley S., Mertens P.R. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J. Biol. Chem. 2009, 284:26928-26940.
78. Rentoukas I., Giannopoulos G., Kaoukis A., Kossyvakis C., Raisakis K., Driva M., Panagopoulou V., Tsarouchas K., Vavetsi S., Pyrgakis V., Deftereos S. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc. Interv. 2010, 3:49-55.
79. Rothenbacher D., Muller-Scholze S., Herder C., Koenig W., Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler. Thromb. Vasc. Biol. 2006, 26:194-199.
80. Salanga C.L., O'Hayre M., Handel T. Modulation of chemokine receptor activity through dimerization and crosstalk. Cell. Mol. Life Sci. 2009, 66:1370-1386.
81. Schittek B., Psenner K., Sauer B., Meier F., Iftner T., Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int. J. Cancer 2007, 120:2110-2118.
82. Schober A., Manka D., von Hundelshausen P., Huo Y., Hanrath P., Sarembock I.J., Ley K., Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002, 106:1523-1529.
83. Seko Y., Cole S., Kasprzak W., Shapiro B.A., Ragheb J.A. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun. Rev. 2006, 5:299-305.
84. Shi C., Zhang X., Chen Z., Sulaiman K., Feinberg M.W., Ballantyne C.M., Jain M.K., Simon D.I. Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. J. Clin. Invest. 2004, 114:408-418.
85. Shibahara K., Sugio K., Osaki T., Uchiumi T., Maehara Y., Kohno K., Yasumoto K., Sugimachi K., Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin. Cancer Res. 2001, 7:3151-3155.
86. Shnyreva M., Schullery D.S., Suzuki H., Higaki Y., Bomsztyk K. Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein. J. Biol. Chem. 2000, 275:15498-15503.
87. Stenina O.I., Poptic E.J., DiCorleto P.E. Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells. J. Clin. Invest. 2000, 106:579-587.
88. Sutherland B.W., Kucab J., Wu J., Lee C., Cheang M.C., Yorida E., Turbin D., Dedhar S., Nelson C., Pollak M., Leighton Grimes H., Miller K., Badve S., Huntsman D., Blake-Gilks C., Chen M., Pallen C.J., Dunn S.E. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005, 24:4281-4292.
89. Suzuki S., Chuang L.F., Yau P., Doi R.H., Chuang R.Y. Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp. Cell Res. 2002, 280:192-200.
90. Ting J.P., Painter A., Zeleznik-Le N.J., MacDonald G., Moore T.M., Brown A., Schwartz B.D. YB-1 DNA-binding protein represses interferon gamma activation of class II major histocompatibility complex genes. J. Exp. Med. 1994, 179:1605-1611.
91. To K., Fotovati A., Reipas K.M., Law J.H., Hu K., Wang J., Astanehe A., Davies A.H., Lee L., Stratford A.L., Raouf A., Johnson P., Berquin I.M., Royer H.D., Eaves C.J., Dunn S.E. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70:2840-2851.
92. Tyner J.W., Uchida O., Kajiwara N., Kim E.Y., Patel A.C., O'Sullivan M.P., Walter M.J., Schwendener R.A., Cook D.N., Danoff T.M., Holtzman M.J. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat. Med. 2005, 11:1180-1187.
93. van Roeyen C.R., Eitner F., Martinkus S., Thieltges S.R., Ostendorf T., Bokemeyer D., Luscher B., Luscher-Firzlaff J.M., Floege J., Mertens P.R. Y-box protein 1 mediates PDGF-B effects in mesangioproliferative glomerular disease. J. Am. Soc. Nephrol. 2005, 16:2985-2996.
94. Vilardaga J.P., Nikolaev V.O., Lorenz K., Ferrandon S., Zhuang Z., Lohse M.J. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 2008, 4:126-131.
95. von Hundelshausen P., Weber K.S., Huo Y., Proudfoot A.E., Nelson P.J., Ley K., Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001, 103:1772-1777.
96. Wang Q., McLoughlin R.M., Cobb B.A., Charrel-Dennis M., Zaleski K.J., Golenbock D., Tzianabos A.O., Kasper D.L. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J. Exp. Med. 2006, 203:2853-2863.
97. Weber C., Weber K.S., Klier C., Gu S., Wank R., Horuk R., Nelson P.J. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 2001, 97:1144-1146.
98. Werner T., Fessele S., Maier H., Nelson P.J. Computer modeling of promoter organization as a tool to study transcriptional coregulation. FASEB J. 2003, 17:1228-1237.
99. Wistow G. Cold shock and DNA binding. Nature 1990, 344:823-824.
100. Wolffe A.P., Tafuri S., Ranjan M., Familari M. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol. 1992, 4:290-298.
101. Yun J.J., Fischbein M.P., Laks H., Irie Y., Espejo M.L., Fishbein M.C., Berliner J.A., Ardehali A. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001, 71:1649-1656.
102. Zernecke A., Liehn E.A., Gao J.L., Kuziel W.A., Murphy P.M., Weber C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006, 107:4240-4243.
103. Zernecke A., Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc. Res. 2010, 86:192-201.
104. Zhang A., Liu X., Cogan J.G., Fuerst M.D., Polikandriotis J.A., Kelm R.J., Strauch A.R. YB-1 coordinates vascular smooth muscle alpha-actin gene activation by transforming growth factor beta1 and thrombin during differentiation of human pulmonary myofibroblasts. Mol. Biol. Cell 2005, 16:4931-4940.